We are now merged!

A New Chapter Begins—Advanced Instruments is now part of Nova Biomedical

Questions?

Advanced Instruments and Nova Biomedical will be doing business under a single, unified brand starting October 15, 2025.

This change marks a significant milestone in our journey to deliver even greater value to you. By combining the strengths of both organizations, we’re enhancing our ability to support your workflows, accelerate innovation, and provide world-class customer service and support across the biopharmaceutical and clinical markets.

Please use this page as a helpful reference to understand what it means for you as a customer.

View Customer Letter

What This Means for You

  • A New Look: You’ll begin to see a refreshed Nova Biomedical logo and visual identity across our communications, product materials, and digital platforms.
  • Expanded Capabilities: With Advanced Instruments now part of Nova Biomedical, we’re growing our portfolio to better support your workflows in biopharmaceutical development and clinical diagnostics.
  • Same Trusted Experience: Your existing contacts, ordering processes, and service interactions remain unchanged. This is a branding update only—not a change to how we work with you.

As we integrate, you’ll benefit from:

  • Shared Mission: Both companies share a focus on innovation, leadership, and improving global patient care.
  • Enhanced Innovation: Integration of complementary technologies and R&D speeds delivery of advanced biopharma and clinical solutions.
  • Expanded Global Reach: An expanded sales network improves product access, service quality, and responsiveness worldwide.
  • Improved Workflow Support: Enhanced support across drug development, bioprocessing, and clinical workflows.
  • Continued Product Excellence: Advanced Instruments continues to lead the way in osmolality testing with expanded capabilities and a continued commitment to excellence.

About Advanced Instruments

Advanced Instruments is a global leader in analytical instrumentation, committed to enhancing accuracy, efficiency, and confidence across biopharmaceutical, clinical, and food & beverage workflows. Trusted worldwide, our innovative solutions include OsmoTECH® and OsmoPRO® micro-osmometers for precise osmolality testing; GloCyte® for automated CSF cell counts; and Anoxomat® for controlled anaerobic and microaerophilic environments. The Artel portfolio ensures reliable liquid handling through validation and automation, while Solentim® accelerates cell line development with advanced imaging and single-cell deposition technologies.

Learn More

Stay Informed

We’re committed to transparency throughout this transition.

Be sure to revisit this page and keep an eye out for emails from Nova Biomedical.

 

FAQ's

The acquisition officially closed on  July 10, 2025, following the execution of a definitive agreement on March 19, 2025. Advanced Instruments and Nova Biomedical are now one company.

The merged company will operate under the Nova Biomedical name. The official name change will take place later this year.

The Advanced Instruments brand will not disappear. It will transition to a portfolio brand specifically associated with our Osmometers, which are recognized as the gold standard for osmolality testing for over 70 years.

Customers will begin seeing updates to the Advanced Instruments name over the coming months. The official transition begins on October 15, 2025.

For now, it’s business as usual. There are no changes to how customers place purchase orders, manage contracts, or engage with either legacy company. If any changes occur that impact customers, we will communicate them in advance. 

Yes. A customer communication regarding the name change was sent the week of July 14, 2025.

The merger creates a premier life science tools platform with:

  • A diversified portfolio of innovative products 
  • Expanded commercial presence in over 100 countries 
  • Enhanced R&D capabilities 
  • Greater potential for sustained growth 

Byron Selman is now the President and CEO of the combined company. Frank Manganaro, Nova Biomedical’s former CEO and founding shareholder, will remain involved in a consulting capacity during the transition.

 Absolutely. We are committed to keeping customers informed and will provide timely updates if and when any changes affect them.

 Have Questions? Contact us for more information

 Fill out the below form and we will be in touch shortly!